doi:10.1016/S2468-1253(23)00068-7 Knudsen LB, Lau J
History of at least one self-reported unsuccessful dietary effort to lose body weight
Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what's possible with this new dose, and that's an opportunity we're excited to provide," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk
And a C18 fatty diacid chain attached at position 26 allows the peptide to bind to albumin in the bloodstream, which slows its clearance and gives it a half-life of approximately seven days
Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) agonists